In a model of heart allograft rejection in adult congeneic rats mismatched for both class I and class II MHC molecules, we analyzed the TCR β chain repertoire of T cells infiltrating rejected allografts [graft-infiltrating T cells (GITC)]. Although all BV families were used by GITC, oligoclonal expansions reflected by an altered distribution of TCR β chain CDR3 lengths were detected throughout the rejection process. Interestingly, expansions involving TCR β chains with common length and BV usage were recurrently found within distinct individuals at late stages of rejection in vivo and after in vitro mixed lymphocyte culture between donor and naive recipient cells. Sequence analysis of the CDR3 regions within recurrent TCR β chains comprising either BV2 or BV13 gene segments demonstrated a complete sequence identity between BV2-BJ2S3 junctions derived from GITC in all individuals tested and the presence of conserved amino acids at constrained CDR3 positions within GITC BV13 ⍣ junctions derived from most individuals. These results suggest the existence of several major alloantigens responsible for expansion of T cell clones bearing a 'public' β chain rearrangement within rejected allografts. The demonstration that such clones are also expanded during in vitro mixed lymphocyte reactions provides an experimental approach which might allow molecular characterization of the above major alloantigens and their possible in vivo targeting.
Introduction
The molecular basis of allorecognition is not yet fully understood. Two pathways of alloantigen recognition have been identified. Host T cells may either interact directly with peptides associated with allogeneic MHC on the surface of donor-type cells (direct allorecognition) (1, 2) or recognize peptides from donor origin that have been processed and presented by host antigen-presenting cells (APC) (indirect allorecognition) (3, 4) . There is clear experimental evidence for a role of both direct and indirect allorecognition pathways in acute allograft rejection (5, 6) .
TCR are heterodimeric receptors with chains encoded by somatically rearranged gene segments like Ig (7) . TCR regions participating to the antigen binding site are the complementarity determining region (CDR)1 and CDR2, encoded by the V genes, and the CDR3, encoded by the rearranged V(D) and J elements (8) . The fine knowledge of the TCR repertoire elicited during an alloresponse is of fundamental importance in understanding the mechanisms underlying allorecognition and in defining the set of allogeneic components recognized in the course of T cell-mediated rejection. In experimental allograft models and in human transplantation, several groups have evaluated the TCR repertoire of activated T cells through different approaches, including immunofluorescence using BV-specific mAb and TCR chain gene amplification and/or sequencing (9) (10) (11) (12) (13) . Whereas some reports have evidenced a restricted TCR-BV usage (14) (15) (16) , others have shown no correlation between expression of a given BV subfamily and the rejection process (17, 18) . In humans, de Palma et al. (19) have shown through analysis of CDR3 size distribution of TCR β chains expressed by in vitro-activated T cells that two HLA-DR1/3 responders stimulated with HLA-DR3/4 cells displayed very similar repertoires, suggesting that alloreactive T cells formed a specific repertoire for each alloantigen. This kind of 'public response', i.e. involving related T cell clonotypes from unrelated individuals has been previously described in several murine models (e.g. 20) .
In this report, we have analyzed the TCR β chain usage among graft-infiltrating T cells (GITC). Firstly, in a quantitative manner with RNase protection assay (RPA) experiments in a model of heart allograft rejection in adult rats, we show that few families are overexpressed in rejected grafts, although most of them are represented. In a qualitative approach, we used a recently described PCR-based methodology (21) that allows the detection of oligoclonal expansions at the CDR3 level within BV families. We show that the BV repertoire is perturbated as compared with peripheral blood leucocytes (PBL) in naive animals and that some oligoclonal expansions with the CDR3 size length, such as BV2 and BV13, are recurrently found among the analysis. At the nucleotide level, our results suggest a selective pressure in the use of some amino acids at specific positions. These in vivo results correlated with the TCR analysis of in vitro mixed lymphocyte reaction (MLR) assays, where similar profiles with the same expansions were obtained.
Methods

Animals
Adult male Lewis rats, 8-12 weeks old, from the LEW.1W (RT1 u ) and LEW.1A (RT1 a ) congeneic strains were obtained from the 'Centre d'é levage Janvier' (France).
Transplantations
Heterotopic heart transplants from LEW.1W (donors) to LEW.1A (recipients) were performed according to Ono and Lyndsey's technique (22) . Graft survival was evaluated daily by examining palpation through the abdominal wall. As previously reported, LEW.1W allografts in LEW.1A recipients were rejected in 13.6 Ϯ 6 days (23).
Proliferation assays
A standard one-way mixed lymphocyte culture was performed as previously described (24) . Briefly, spleen cell suspensions were prepared from naive animals (25) and 2ϫ10 6 LEW.1A responder cells were cultured with an equal number of irradiated LEW.1W stimulator cells in 10 ml of medium consisting of RPMI 1640 supplemented with 10% heat-inactivated FCS, 2 mM L-glutamine, 100 U/ml of penicillin/streptomycin, 1 mM sodium pyruvate and 5ϫ10 -5 M 2-mercaptoethanol. Daily, from day 0 to 7 of culture, 500 µl aliquots were removed from the mixed lymphocyte culture and RNA was isolated from the cells (see below). In parallel, cell proliferation was assessed daily by measuring [ 3 H]thymidine incorporation as described previously (24) .
RNA extraction and cDNA synthesis
Total RNA from organs (spleens and allografts) was isolated according to the guanidinium isothiocyanate procedure and purified by cesium chloride ultracentrifugation (26), whereas 
a Each BJ primer is 5Ј-labeled (X) with a Fam fluorophore (Applied Biosystems).
total RNA from cell suspensions was prepared as described by Chomczynski and Sacchi (27) . Single-strand cDNA synthesis was performed from 10 µg total RNA using the avian myeloblastosis virus reverse-transcriptase kit (Life Science, Gaithersburg, MD) according to the manufacturer's instructions.
Oligonucleotides
Rat TCR-BV and TCR-BC primers have been previously described (28) . Table 1 shows the sequences of labeled BJ primers used in run-off experiments. Oligonucleotides specific for each of the 12 BJ genes correspond to the non-coding strand (29) . Fluorescent primers were labeled (X) at the 5Ј end with the Fam fluorophore (Applied Biosystems, Foster City, CA).
PCR amplification and run-off reactions for analysis of CDR3 lengths
PCR and run-off reactions were performed essentially as described elsewhere (28, 30, 31) . Briefly, cDNA (corresponding to 50 ng of total RNA) was subjected to amplification for 40 cycles in a 50 µl reaction mixture containing 0.5 µM of each primer (TCR-BC together with each of the 20 TCR-BV primers), 0.2 mM dNTPs, 1.5 mM MgCl 2 , 1ϫ Taq polymerase reaction buffer and 1 U Taq DNA Polymerase (Life Science). Following amplifications, 2 µl of each PCR product was subjected to three cycles of elongation (run-off) with a dyelabeled TCR-BCRO-or BJ-specific primer (0.1 µM) in a final volume of 10 µl, containing 0.2 mM dNTP, 3 mM MgCl 2 and 0.2 U of Taq DNA polymerase in 1ϫ Taq polymerase reaction buffer. Then 10 µl of a 30 mM EDTA-formamide solution was added to each reaction tube. Negative controls for each BV subfamily were made with water instead of cDNA.
Electrophoresis and fragment analysis
Heat-denaturated run-off reaction product (2 µl) was separated on a 6% polyacrylamide 8 M urea gel. After migration on a 373A DNA sequencer (Applied Biosystems), the size and the intensity of fluorescence of each peak were deter-mined using Immunoscope software as previously outlined (21) .
Direct sequencing of PCR products
BV-BC or BV-BJ PCR products were purified and sequenced as described (32) .
Cloning of BV-specific PCR products cDNA was amplified as described above with a sense BV13 primer (5Ј-TAGAATTCATGGGCACCGGGCTTCTTG -3Ј) and an antisense TCR-BC primer (5Ј-CACTGATGTTCTGTGTGA-CA-3Ј) specific for both TCR-BC1 and TCR-BC2 rat genes. PCR products were separated on an agarose gel, the band extracted and purified using the Prep-A-Gene kit (BioRad, Ivry-sur-Seine, France). PCR products were then cloned with the dephosphorylated pBluescript II SKϩphagemid (Stratagene, La Jolla, CA) using the SureClone kit (Pharmacia, Saint-Quentin-en-Yveline, France) electroporated into Epicurian Coli XL1-blue MRF' competent Escherichia coli (Stratagene) and cultured on solid LB medium supplemented of X-Gal and IPTG at 37°C overnight. White colonies were selected and cultured in liquid LB medium for at least 6 h at 37°C under agitation. Plasmid DNA was recovered by the alkaline lysis method (33) , and digested with XhoI and XbaI (Eurogentec, Angers, France) to confirm insertion of clones.
Sequencing of BV13-cloning PCR products
Cloned PCR products were sequenced using the ∆Taq sequencing kit (Amersham, Les Ulis, France) according to the manufacturer's instructions, using a nested TCR-BV13 primer (28) .
RPA
A two-set multiprobe of 19 BV-specific riboprobes (kind gift of Dr A. N. Theofilopoulos, La Jolla, CA) was used in RPA experiments essentially as described (34) . Riboprobes were synthesized and labeled using T7 RNA polymerase (Promega, Madison, WI) with [α 32 P]UTP. Sets of 5ϫ10 5 c.p.m. each were hybridized with 5-40 µg of total RNA from grafts or spleens for 12 h at 56°C. After treatments with RNase A (5 µg/ml; Boehringer Mannheim, Mannheim, Germany) and T1 (10 U/ ml; Pharmacia), protected probe/target mRNA duplexes were phenol-chloroform extracted, ethanol precipitated and electrophoresed on a 6% polyacrylamide sequencing gel. Dried gels were autoradiographed on Kodak film with intensifying screens at -70°C for 4-24 h. BV was quantified on the basis of peak heights from densitometric scans of autoradiographs with the Hoefer densitometer and RNA amounts were normalized between probe sets using the BV2 signal.
Results
Quantitative analysis of BV usage in GITC
In order to assess the representation of each BV family within rejected hearts, we have analyzed the repertoire by RPA. Four different grafts, harvested on days 3 and 5 after transplantation, were processed and compared with the repertoire Fig. 1 . Relative TCR-BV expression levels in rejected allografts and spleen. Total RNA (5-40 µg) was assayed from spleens and rejected grafts on days 3 and 5 for each probe set. Autoradiographic profiles were scanned with a densitometer, and graph represents the RNA amounts for each BV family analyzed in two rejected allografts on days 3 and 5. found in the spleens from naive animals ( Fig. 1) . Most of the families were found within the grafts, but the percentage varied with time and only four BV families were found overrepresented within the grafts as compared with spleen. The most expanded was the BV9 both on days 3 and 5. BV8.3, BV13 and BV16 were also greater represented on day 5. Thus, the BV repertoire within rejected grafts was not restricted in a representative fashion, but in a quantitative one.
BV repertoire alterations at the CDR3 level
Since nearly all the BV families were represented within the grafts, we have analyzed the TCR-BV repertoire at the CDR3 level, in order to detect oligoclonal expansions similarly expressed between the different animals. We used a previously described PCR-based technology where fluorescent products which have been extended through the CDR3 regions of various sizes in each BV family, were loaded on an automated DNA sequencer and analyzed with the Immunoscope software. This analysis yields both the VDJ size distribution and the intensity of the signal (21) . In spleen cells or PBL isolated from naive rats, TCR-BV families displayed typical polyclonal profiles, i.e. with an average number of eight peaks spaced by three nucleotides, distributed in a Gaussian-like fashion (Fig. 2 , grey background profiles). Similar profiles have been described in both mice and humans (21, 35) . The area of each size peak is proportional to the quantity of TCR β transcripts of the corresponding CDR3 size in the sample analyzed, thus giving a true quantitative picture within a designated BV family.
To analyze TCR-BV usage in GITC during the rejection, we performed the repertoire study on days 1, 3, 5 and 7 postgraft, with five animals at each time point. On days 1 and 3 post-graft, almost all BV families were detected, with polyclonal profiles in each (data not shown). On day 5, as shown for one representative animal (Fig. 2, black profiles) , the TCR-BV profiles showed alterations as compared to the naive repertoire (Fig. 2, grey profiles) . In syngeneic grafts, only few BV families were detected, differing from one animal to another and with highly restricted profiles, i.e. one or two peaks per family (n ϭ 3, data not shown). However, even though the profiles in GITC from rejecting grafts were extensively modified as compared to naive ones, the TCR-BV repertoire was not restricted since almost all TCR-BV families were detected in allografts. It should be noted that in some animals some TCR-BV families which differed from one individual to another were absent on day 1 and/or 3 after transplantation.
We also analyzed the TCR-BV repertoire during a one-way primary MLR using LEW.1W (RT1 u ) spleen cells as stimulators and LEW.1A (RT1 a ) spleen cells as responders. Both stimulator and responder cells were isolated from naive rats. After 1 day of culture, the TCR-BV profiles were similar to those obtained in spleen or PBL from a naive animal (data not shown). As early as day 3 we observed modifications within some TCR-BV families as compared to naive profiles (data not shown) and on day 5 (Fig. 2 , white foreground profiles) and 7 (data not shown) these profiles became more perturbated with several prominent clonal expansions.
Since all recipients are from the same strain but differ from the congeneic heart donors for both MHC class I and class II molecules, we speculate that the recipients will respond in a similar way to alloantigen (public response), but also in a private way, i.e. each animal mounts a response of its own. In an attempt to detect common dominant T cell expansions shared by different recipients, we compared the 20 TCR-BV profiles obtained from five rejected hearts at each time point. On days 1 and 3 post-graft, profiles were polyclonal and did not display dominant expansions. On days 5 and 7, most BV families shared one or two dominant expansions compared to naive profiles, as shown for BV12 (with a PCR product of 195 nucleotides), BV15 (173 and 181) or BV20 (208) on Fig.  2 (black profiles) . However, such expansions are found in one and sometimes two animals, suggesting a reproducible response between a subset of recipients, but not for all. In fact, we have focused our study on families where a given size peak was reproducibly found dominant over the polyclonal background. Three families displayed such dominant peaks which arise among the polyclonal background in the different recipients: BV2, BV10 and BV13. Interestingly, BV13 has been shown to be overexpressed by RPA, but not the BV2 family (Fig. 1 ). This choice of analyzing commonly found dominant expansions did not exclude that these families are the most alloreactive. The BV9 family which was highly represented within heart allografts ( Fig. 1) showed polyclonal profiles without common dominant peaks between the animals, at the BV level as well as at the BJ level (data not shown).
In all cases, BV2, BV10 and BV13 GITC profiles were not profoundly altered on days 1 (not shown) or 3 ( Fig. 3B) after grafting, but prominent peaks with similar length were detected on days 5 and 7 after grafting (Fig. 3B) . BV2-BC profiles comprised a dominant peak with a length of 164 nucleotides, corresponding to a CDR3 size length of 5 amino acids, according to Kabat et al. (36) . The dominant peaks found in BV10 and BV13 subfamilies had a length of 135 and 162 nucleotides respectively, both corresponding to a CDR3 size length of 8 amino acids (Fig. 3B) . Moreover, when we focused on these TCR-BV-specific families in MLR experiments, we found a similar modification according to time culture; namely the same peaks emerged from the polyclonal profiles on days 5 and 7, i.e. the kinetics were comparable to those seen in rejected grafts (Fig. 3C) .
Inter-individual expansions of T cell clones expressing TCR-BV chains with similar length and restricted BV-BJ usage
BV-BC analysis gave a global picture of the repertoire in rejected allografts at different time points. To obtain more specific informations about the expansions observed at the BV-BC level, we performed the next step by using labeled TCR-BJ primers specific for the twelve known TCR-BJ segments in rats (29) . In agreement with previous studies in mice (21) , BV2-, BV10-and BV13-BJ analysis of PBL from naive animals yielded polyclonal profiles (data not shown). In contrast, BV2 and BV13 CDR3 analysis revealed the predominence of common BV/BJ peaks shared by most individuals. For instance five of five animals showed a common dominant BV2-BJ2S3 peak with a CDR3 size length of 5 amino acids (position 128 in Fig. 4B ) on days 5 and 7 after grafting. This BV2-BJ2S3 expansion was similar in amino acid size to the one observed at the BV2-BC level. Interestingly, similar results were obtained when analyzing in vitro MLR cultures (Fig. 4C) . It should be mentioned though that the common peaks were detected on days 5 and 7 only, but markedly differ from one individual to another at earlier time points (Fig. 4B) . Taken together these results suggest a selective expansion of a T cell subset bearing this specific BV2-BJ2S3 rearrangement.
In the BV13 family, we observed that BV13-BJ1S2, BV13-BJ1S4, BV13-BJ2S4 and BV13-BJ2S5 profiles displayed a dominant peak which was reproducibly found in the different grafts analyzed. In BV13-BC analysis, the dominant peak corresponded to a CDR3 size length of 8 amino acids (Fig.  3 ) and the expansions observed in the four BV13-BJ profiles mentioned above also corresponded to a CDR3 size length of 8 amino acids. Figure 5 shows the alignment of different BV13-BC, -BJ2S4 and -BJ2S5 profiles obtained from different animals on days 5 (Fig. 5A) and 7 (Fig. 5B) . Moreover, these dominant expansions were also found in MLR experiments (Fig. 5, black profiles) . In GITC from rejected allografts, BV10-BJ analysis showed perturbated polyclonal profiles on days 5 and 7 but no correlations, i.e. no common dominant peaks with the same length and BV-BJ combination were derived from the different animals studied (data not shown).
Expansion of T cell clones with a 'public' BV2 sequence within GITC
BV2-BC and BV13-BC analysis displayed a predominant peak but the polyclonal background was too high, and therefore direct sequencing of the PCR products with a TCR-BC primer as has been described elsewhere was not possible (32) . Therefore, when a single peak was obtained in Immunoscope analysis, we sequenced these PCR products using TCR-BJ primers.
BV2-BC PCR products from allografts taken on days 5 and 7 were sequenced with the BJ2S3 primer (n ϭ 8). The same sequence(s) corresponding to in-frame transcripts were obtained in all animals; in all cases, this sequence led to two possible amino acid sequences since two nucleotides could not be discriminated, leading to either a serine or an arginine at position three following the conserved cysteine (i.e. at the first position in the CDR3 loop) ( Table 2 ). As expected from Immunoscope analysis, the CDR3 region had a length of 5 amino acids.
Characterization of selected motifs within BV13 sequences derived from GITC
Although a predominant 8 amino acid peak was evidenced within BV13 transcripts, no readable sequences were obtained when we tried to directly sequence material amplified Fig. 3 . Kinetic analysis of BV2, BV10 and BV13 subfamilies in GITC from rejected allografts and in MLR. Total RNA was extracted from rejected heart allografts on days 3, 5 and 7 (n ϭ 4 animals at each time point). BV-BC analysis was performed as descibed in Fig. 1 . Graphs show BV2-, BV10-and BV13-BC profiles obtained from (A) naive LEW.1A rat PBL, (B) one representative animal for each day post-graft and (C) one representative MLR for each day of culture. Graphs represent the intensity of fluorescence in arbitrary units as a function of run-off product size in nucleotides.
with the BV13 primer, regardless of the TCR-BJ primer used. Hence this suggested an expansion of a polyclonal T cell population expressing TCR-BV13 chains with restricted length. Therefore, we cloned BV13-BC PCR products from rejected hearts from five individuals, from a 7-day MLR, and from naive LEW.1A PBL as control and sequenced the bacterial clones with a BV13-nested primer. More than 200 clones were analyzed, from which 137 and 26 in-frame VDJ Fig. 4 . BV2-BJ2S3 analysis.Reverse-transcribed RNA from rejected heart allografts and cultured cells was amplified to saturation with BV2-and TCR-BC-specific primers. Run-off reactions were then performed using the BJ2S3 fluorescent primer. Analysis of run-off products was assessed as described in Fig. 1 . BV2-BJ2S3 profiles (A) in spleen cells from a naive animal, (B) in rejected grafts from different animals on days 3, 5 and 7, and (C) in MLR on same days of culture. Graphs represent the intensity of fluorescence in arbitrary units as a function of run-off product size in nucleotides.
sequences were obtained from GITC/MLR and naive rat, respectively.
Of the sequences derived from GITC or MLR-activated T cells, 43% had a CDR3 size of 8 amino acids (59 of 137), 13% a CDR3 size of 9 amino acids (18 of 137), and 28% had CDR3 sizes of 10 and 11 amino acids (38 of 137) ( Table 3) . The remaining 16% corresponded to sequences with CDR3 sizes of 6, 7 or 13 amino acids. In the control sample, we obtained 27 and 35% of VDJ junctional sequences with a size of 8 and 9 amino acids respectively (Table 3) . These data are in accordance to Immunoscope analysis, which demonstrated a predominance of 8 amino acid BV13 rearrangements in GITC but the presence of two dominant peaks corresponding to CDR3 size lengths of 8 and 9 amino acids in naive animals (Fig. 2) .
Regarding the sequences themselves, BV13 CDR3 sequences were at first sight highly heterogeneous even when analyzing sequences with the same length. Since CDR3 size of the predominant peak within GITC (8 amino acids) was shared by a relatively large fraction of naive PBL (Table  3) , sequence heterogeneity could be due to the presence of a large fraction of bystander T cells, non-specifically trapped Fig. 5 . BV13-BJ analysis in allografts and MLR. Reverse-transcribed RNA from heart allografts and cultured cells was amplified to saturation with BV13-and TCR-BC-specific primers. Run-off reactions were then performed using the TCR-BC-, BJ2S4-and BJ2S5-specific fluorescent primers. Analysis of run-off products was assessed as described in Fig. 1 . Analysis was performed with heart allografts (grey profiles) and MLR (black profiles) on days 5 (A) and 7 (B). Graphs represent the intensity of fluorescence in arbitrary units as a function of CDR3 size length in amino acids. within the rejected graft due to local release of proinflammatory cytokines. Alternatively, such an heterogeneity might be explained by rather limited TCR constraints imposed by a small set of antigens. In this respect, data from the literature suggest that CDR3 sequences of TCR selected against a given MHC-peptide complex are seldom identical but frequently share similar length and few residues at particular positions (generally the second and third amino acids of the CDR3 loop, which both correspond to N-and/or D-encoded residues). To detect possible selection of recurrent junctional motifs, we reasoned that such amino acids should be preferrably found within repeated sequences derived from a given individual (i.e. presumably derived from clones expanded in situ) or within identical sequences shared by distinct individuals. Therefore, we aligned repeated sequences by CDR3 size and looked for homologies, particularly at 'constrained' positions (i.e. amino acids at positions 2 and 3 of the CDR3 loop). Through this strategy, four major recurrent motifs were evidenced within repeated sequences: Ser, Arg or Phe at position 2 within CDR3 sequences of 8 or 9 amino acids and Leu/Phe at positions 2/3 within CDR3 sequences of 10 or 11 amino acids (see amino acids in bold italics, Table   4 ). Significantly, in agreement with selection of these motifs, their frequency at the same position within nonrepeated GITC sequences or within sequences derived from naive animals turned out to be much lower than within repeated sequences (Table 4 and 5 ). In particular, while Ser at position 2 was found in four of eight and one of three repeated sequences of 8 and 9 amino acids respectively, it was found in four of 33 non-repeated GITC sequences only and was not found in any of CDR3 sequences derived from naive rat (Table 5) . Similarly, Leu/Phe at positions 2/3 were found in four of seven repeated sequences of 10 and 11 amino acid size but in only a min fraction of non-repeated sequences derived from GITC or naive T cells (Table 5 ). In the case of CDR3 sequences with Phe or Arg at position 2, although enriched within repeated GITC sequences, such motifs were also found within sequences from naive rat and thus, their selection could not be clearly established.
In conclusion, these results suggest that cells expressing at least two sets of sequences (Ser2 and Leu2/Phe3 within sequences of 8/9 and 10/11 amino acids) are specifically expanded within rejected grafts. Moreover, the fact that these sequences were shared by almost all individuals studied (e.g. repeated Ser2/8 amino acid CDR3 were found in four of five individuals) and were also expanded during in vitro MLR suggests the existence of several dominant alloantigens whose recognition result in in vivo and in vitro expansion of T cells with a relatively conserved repertoire.
Discussion
Analysis of TCR usage in different experimental or clinical situations during allorecognition has been approached in several ways. These include using mAb (37), RPA (34), anchored PCR (12) or cloning and sequencing (10) . In the present study, we used a model of heart allograft rejection using congeneic Lewis rats, mismatched for both class I and class II MHC molecules (23) . To assess the TCR repertoire usage during the rejection process, we firstly performed a quantitative study by RPA (34) . We observed that nearly all the BV families were detected within allografts on days 3 and 5 ( Fig. 1) . Surprisingly, in a heart allograft model in rats with ACI-to-LEW combination, Shirwan et al. found only two BV families expressed in grafts (16) . Other authors have shown such restrictions in biopsies from human allografts (15, 38) , but our results are in accordance with the findings of different groups which have described a heterogeneous usage of the BV families (18, 39) . However, we show here that even though nearly all the BV families are detected, only four were overexpressed as compared to the level of expression in naive spleen (Fig. 1) . Thus, we consider that in our model the TCR-BV usage is restricted in a quantitative manner.
In addition, we have performed a qualitative measurement of the β chain usage with a technology called Immunoscope, which semi-quantitatively analyzes the β chain repertoire at the CDR3 level, avoiding the need to grow T cells in vitro (21) . For each TCR-BV family in normal samples profiles obtained are distributed in the six to eight size peaks spaced by three nucleotides, corresponding to in-frame transcripts. The area of each size peak is proportional to the quantity of TCR β transcripts of the corresponding CDR3 size in the sample analyzed, giving a quantitative distribution within each TCR-BV family. Each peak corresponding to a given CDR3 length usually contains multiple distinct sequences, but an increase in the height and area of a size peak commonly signals a monoclonal expansion occuring against a polyclonal background (21,28). As expected, nearly all the BV families were detected within allografts (Fig. 2) .
In an attempt to detect 'public' clonal expansions emerging during the rejection time course, we first compared the GITC profiles obtained from different animals. This preliminary analysis revealed the existence of dominant peaks shared by several individuals within BV2, BV10 and BV13 families (Fig.  3) . We then analyzed TCR-BJ usage within these TCR-BV families and found dominant peaks amplified with some BV-BJ primer combinations, which displayed the same CDR3 size lengths as those detected at the BV-BC analysis level (Figs 4 and 5) . This result suggested a size restriction in the recognition of allodeterminants. Interestingly, the predominant peaks found in GITC both at the BV-BC and BV-BJ analysis levels were also detected in MLR (Figs 2, 3 and 4) . In a previous report (28) , we analyzed the GITC TCR-BV repertoire in this LEW.1W to LEW.1A model where heart allograft tolerance was induced by pre-transfusing the recipient with donorspecific blood (23) . Of note, the profiles observed in rejected hearts as well as in MLR were different from those obtained in tolerated grafts and the dominant expansions were not those described above, whatever the day analyzed (data not shown). Hence these results suggest that the dominant peaks observed within rejected grafts are derived from cells specifically involved in the rejection process.
With RPA, the BV9 family seemed to be one of the most expressed as compared with spleen. However, when the CDR3 size length profiles from the different grafts harvested on different days were compared, they were highly polyclonal although not in a Gaussian-like fashion (data not shown). No commonly found size expansions were obtained. This result suggests that this BV9 family is involved in the allorecognition; however, each animal uses it in its own way.
Regarding the clonality of the T cell population expressing TCR chains with predominant CDR3 length, strikingly different results were obtained when analyzing BV2 and BV13 transcripts at the nucleotide level. In the former case, we could show, by a direct sequencing procedure, the usage of a highly conserved sequence within all individual studied (Table  2) , thus demonstrating expansion of common T cell clones expressing a 'public repertoire', at least a conserved V β chain. In the latter case, the BV13 sequences turned out to be much more diverse but we could evidence constraints both at the CDR3 size and amino acid level. In particular we found a Ser residue at the second position of the CDR3 loop which was specifically found within CDR3 clones of 8 and 9 amino acid length was enriched within repeated sequences but was not found in control samples (Tables 4 and 5 ). It was surprising to find common sequences from MLR assays and GITC, which suggest a limited heterogeneity for MHC-peptide complexes, inducing emergence of public clonotypes as for the BV2 family, but also clonotypes which, although having distinct sequences, displayed some common characteristics such as length community and recurrence of motifs showing the same hydropathic features. The emergence of the BV2 public clone could be explained by its high affinity for some allodeterminants (20) together with an already high frequency prior to the selection process. In support of this, it should be mentioned that the public BV2 sequence, like many previously described public sequences (40) , shows limited junctional modifications (and in particular few N additions) which might explain its possible over-representation prior to selection. Concerning the BV13 family, the CDR3 sequences, though of similar size, were much more diverse, suggesting expansion of clones with similar specificity but perhaps distinct affinity for the same MHC-peptide complex. Similar conservation of CDR3 size but not sequence of TCR β chain has been described in several previous studies. For instance, Taylor et al. have analyzed TCR-BV usage from hybridomas specific for influenza virus hemagglutinin and found a conserved BV8.3 rearrangement usage with a common CDR3 size (41) . Similar results were obtained by Kelly et al. using ovalbumin-specific hybridomas (42) . Following immunization of mice with pigeon cytochrome c antigen, McHeyzer-Williams and Davis analyzed the primary and memory T cell response (43) , and showed a selection for homogeneity in the length of the CDR3 which occured before selection of some characteristic amino acids, suggesting a hierarchy between these two TCR parameters. There are many other reports which show such a restricted usage of CDR3 length of TCR-BV chains when analyzing responses against known antigens. However, this work is to our knowledge the first report which describes a similar size selection in allorecognition both in vivo and in vitro (see below). Different groups have studied TCR-BV usage of T cells activated in the course of in vivo and in vitro alloresponses in both animal models and humans. While some groups reported a diverse TCR usage (17, 18, 37, 44, 45) , others described a restricted one (14, 16, 46) . However, these analyses were performed either with biopsies (18) , with freshly isolated GITC (44) or with alloreactive T cell lines obtained from biopsies (14, 37) . The reports described essentially the TCR-BV family usage in a semiquantitative manner (16) or analyzed the presence or absence of different TCR-BV families. Recently, using a similar methodology as Immunoscope, Gorski et al. described the TCR-BV repertoire in normal human individuals and in bone marrow recipients and showed modified profiles in recipients, but without recurrent restrictions. Interestingly, they also described conserved alloreactive repertoires in vitro using unrelated responders (19) . Their results are in accordance with our findings of restricted profiles at the CDR3 level for given TCR-BV families both in vitro and in vivo in congeneic animals for which the diversity of processed autologous peptides is likely greatly reduced. Together, these results would nevertheless indicate that the diversity of determinants triggerring an allogeneic response is much more limited than initially thought. Moreover, the present demonstration that common T cell expansions evidenced in vivo can be also detected in vitro provides an experimental approach which might allow molecular characterization of the allodeterminants responsible for public T cell responses.
Besides the interest to tackle allorecognition in an in vivo context, our model should allow us to determine the pathogenicity of such public clones and their possible controls by the clones induced after transfusion in tolerated recipients (28) . Such a study could be an in vitro marker in T cell response directed against allocomplexes allowing us to follow alloresponse emergence in vivo. There are some interesting reports showing the targeting of specific T cell subsets to commit an immune response. Goss et al. have obtained the survival of skin and heart allografts in mice by depleting T cells bearing the TCR-BV8 chain with a mAb (47) . Moreover, by using a synthetic peptide derived from the TCR-BV8 variable region, they blocked the in vitro and in vivo allogeneic responses to mouse class I MHC molecules L d , and suggested that this peptide functions as an antagonist (48) . Recently, Waisman et al. obtained interesting results in a model of experimental autoimmune encephalomyelitis in mice by vaccinating the immunized animals with naked DNA encoding the TCR-BV8S2 chain, therefore committing the T cell response towards the T h 2 side instead of T h 1, unlike treated mice (49) . These reports and others suggest that when reactive T cells are determined, it might be possible to block their effector functions by specific targeting. It will be interesting now to have a more precise idea about the nature of the T cells involved in different types of immune responses (e.g. tolerance versus rejection). Our results and those from other groups (15, 19, 50, 51) suggest that it might be possible to detect alloreactive cells responsible for either one or the other process.
